Gary K. Lee - Feb 24, 2023 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Scientific Officer
Signature
/s/ Hector Casab, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Feb 24, 2023
Transactions value $
$0
Form type
4
Date filed
2/28/2023, 05:17 PM
Previous filing
Feb 14, 2022
Next filing
Nov 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LYEL Common Stock 4.7K Feb 24, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +600K $0.00 600K Feb 24, 2023 Common Stock 600K $2.13 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
F2 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.